1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Infection prevention & Control Market: By Infections (Microbial and Others) By Antimicrobial Drugs (Antibacterial & Others) By Accessories and Equipment (Disinfectants and Others) By End User (Equipment & Drug Usage) & By Geography-Forecast(2015-2020)

Infection prevention and Control (IPC) is a rapidly growing field in the healthcare industry. The proper usage of the IPC products all across the globe has the potential to revolutionize the complete healthcare industry, making it disease free. The market opportunity for IPC is promising, yet conflicting financial Incentives has created uncertainty on how stakeholders can capitalize. The market for Infection prevention is estimated to increase with a CAGR of 5.3% during the forecast period 2015-2020. Infection prevention and control market is experiencing significant growth with the increase in awareness among the people, elderly & aging population, and number of surgeries and proper donning and doffing of Hospital Housekeeper which prevents in the spread of the contagious waste.

Infection prevention and control is the major and significant step in the development and maintenance of products in the Medical Devices, Pharmaceuticals, and food & beverage industries. The adoption of various means of personal protective equipment, disinfection, sterilization and in-house sterilization procedures by hospitals and end users industries has revolutionized the healthcare industry. Sterilization and disinfection protect different products and materials from being contaminated by microbes. The disinfection and sterilization market is going to expand with a CAGR of 6.2% during the period under study. The integration of technologies into traditional healthcare systems is one of the most influencing trends that will drive the growth of this market. The technological advancements will facilitate the availability and implementation of cost-effective technologies across a range of healthcare facilities. The introduction of technically enhanced instruments likes portable autoclaves, In-House & ethylene oxide (EtO) advanced sterilization and so on has resulted in the drastic swing from the previous used equipment’s such as steam sterilizer.

The IPC market by anti-microbial drugs in North America in 2014 was valued at $XX billion and is projected to grow at a CAGR of 4.5% during the forecast period. The North American region has been concentrating on relatively easy commercial drugs which were driven by the increase in chronic diseases. This has led to the development of vaccines, since these are specific for a particular infection. The cost of the vaccines varies as per the infected microbes. Thus, followed by anti-bacterial drugs, vaccines show the highest growth rate of 4.8% towards the increasing demand of anti-microbial drugs, where most patients would be managed with a short course of therapy in comparison to the generic antibiotics. According to the World Health Organization, 30.85% of the globally registered hospitals are in the Americas. Moreover, the rapidly aging population in the U.S., Canada and Mexico will drive the need for efficient anti-microbial drugs in hospitals and senior care centres in this region.

The global infection prevention and control market is segmented into bacterial, fungal and viral infections based on the types of microbial infections. In 2014, bacterial infections dominated the market with 44% of the global market share in infection prevention and control market, followed by viral infections, which occupied 39%.

Table Of Contents

Infection prevention and Control Market: By Infections (Microbial and Others) By Antimicrobial Drugs (Antibacterial and Others) By Accessories and Equipment (Disinfectants and Others) By End User (Equipment and Drug Usage) and By Geography-Forecast(2015-2020)
1. Global Infection Prevention and Control - Market Overview
2. Global Infection Prevention and Control Market - Executive Summary
3. Global Infection Prevention and Control - Market Landscape
3.1. Market share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End-User Profiling
3.2.3. Patent Analysis
3.2.4. Top 5 Financial Analysis
4. Global Infection Prevention and Control - Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Global Infection Prevention and Control Market - Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunity Analysis
5.3. Product Life Cycle Analysis
5.4. Pricing Analysis
6. Global Infection Prevention and Control Market - By Infections
6.1. Microbial Infections
6.1.1. Bacterial Infection
6.1.1.1. Mycobacterium tuberculosis
6.1.1.2. Clostridium Difficile
6.1.1.3. E. Coli
6.1.1.4. Helicobacter pylori
6.1.1.5. Salmonella
6.1.1.6. Others
6.1.2. Viral Infection
6.1.2.1. Ebola Virus
6.1.2.2. Human Immunodeficiency Virus (HIV)
6.1.2.3. Herpes Simplex Virus
6.1.2.4. Yellow Fever
6.1.2.5. Dengue Viruses
6.1.2.6. Others
6.1.3. Fungal Infection
6.1.3.1. Cryptococcus gattii
6.1.3.2. Aspergillis
6.1.3.3. PCP: Pneumocystis Pneumonia
6.1.3.4. Fungal Keratitis
6.1.3.5. Dermatophytes
6.1.3.6. Others
6.2. Healthcare Associated Infection
6.2.1. Hospital Acquired Infection
6.2.1.1. Central Line-associated Bloodstream Infection (CLABSI)
6.2.1.2. Catheter-associated Urinary Tract Infection
6.2.1.3. Surgical Site Infection
6.2.1.4. Ventilator-associated Pneumonia (VAP) Infection
6.2.2. Community acquired Infection
6.2.2.1. Methicillin-resistant Staphylococcus aureus (MRSA) infection
6.2.2.2. Community-acquired pneumonia
7. Global Infection Prevention and Control Market - By Anti-Microbial Drugs
7.1. Anti- Bacterial Drugs
7.2. Anti- Viral Drugs
7.3. Anti-fungal Drugs
7.4. Vaccines
8. Infection Prevention and Control Market - By Accessories and Equipment
8.1. Personal Protective Equipment
8.1.1. Gloves
8.1.2. Surgical Masks and Respirators
8.1.3. Surgical Drapes and Gown
8.1.4. Surgical Foot Covers
8.1.5. Medical Safety Glasses
8.1.6. Others
8.2. Disinfectants
8.2.1. Hand Sanitizers
8.2.2. Disinfectant Wipes
8.2.3. Surface Disinfectants
8.2.4. Instrument Disinfectants
8.2.5. Surgical Disinfectants
8.2.6. Environmental Disinfectants
8.2.7. Others
8.3. Sterilization
8.3.1. Medical Device Sterilization Equipment
8.3.1.1. Wet/ Steam Sterilization (Autoclave)
8.3.1.1.1. Vertical Autoclave
8.3.1.1.2. Horizontal Autoclave
8.3.1.1.3. Portable Autoclave
8.3.1.2. Dry Heat Sterilization
8.3.1.3. Low Temperature Sterilization
8.3.1.3.1. In-House Steam Sterilization
8.3.1.3.2. Ethylene Oxide (EO) Sterilization
8.3.1.3.3. Gamma and eBeam Sterilization
9. Global Infection Prevention and Control Market - By End User Industry
9.1. End Users: By Equipment Usage
9.1.1. Hospitals and Clinics
9.1.2. Medical laboratories
9.1.3. Manufacturing Units
9.1.3.1. Pharmaceuticals
9.1.3.2. Medical Devices
9.1.3.3. Food and Beverages Industry
9.2. End Users: By Drug Usage
9.2.1. Individuals and Patients
9.2.2. Nursing and Senior care Centers
10. Global Infection Prevention and Control Market - Regulatory Scenario
11. Global Infection Prevention and Control Market - Geographic Analysis
11.1. Introduction
11.2. North America
11.2.1. US
11.2.2. Canada
11.2.3. Mexico
11.2.4. Others
11.3. Europe
11.3.1. France
11.3.2. Germany
11.3.3. Italy
11.3.4. Spain
11.3.5. UK
11.3.6. Others
11.4. APAC
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Korea
11.4.5. Others
11.5. ROW
11.5.1. Saudi Arabia
11.5.2. South Africa
11.5.3. Brazil
11.5.4. Russia
11.5.5. Others
12. Market Entropy
12.1. New Product Launches
12.2. MandAs, Collaborations, JVs and Partnerships
13. Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolios)
13.1. ABBOTT LABORATORIES (ABBOTT DIACNOSTICS)
13.2. ALERE
13.3. ANSELL LIMITED
13.4. ASTRAZENECEA
13.5. BARD (CR) INCORPORATED
13.6. BECTON, DICKINSON AND COMPANY
13.7. BELIMED
13.8. CANTEL
13.9. COVIDIEN PLC
13.10. GETINGE GROUP
13.11. HOLLISTER INCORPORATED
13.12. JOHNSON and JOHNSON
13.13. KIMBERLY-CLARK
13.14. MERCK and CO
13.15. PFIZER
13.16. ROCHE
13.17. SIEMENS AG
13.18. SUPERMAX CORPORATION
13.19. TERUMO CORPORATION
13.20. 3M COMPANY
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
14. Appendix
14.1. Abbreviations
14.2. Sources
14.3. Research Methodology
14.4. Bibliography
14.5. Compilation of Expert Insights
14.6. Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.